Merck’s Saphris Gets FDA Letter After Taking Informant To Lunch
This article was originally published in The Pink Sheet Daily
Executive Summary
A complaint to the “Bad Ad” program that a speaker had promoted an unapproved use for Merck’s atypical antipsychotic Saphris leads FDA’s Office of Prescription Drug Promotion to issue a “notice of violation” letter.
You may also be interested in...
"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One
In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.
Forest Admits To Knowingly Obstructing FDA Inspection In Guilty Pleas On Levothroid, Celexa Marketing
Forest Pharmaceuticals reached a $313 million settlement with the Department of Justice to resolve criminal charges of obstructing an FDA inspection and distributing a misbranded drug and civil False Claims Act allegations.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: